Agios Pharmaceuticals (MEX:AGIO) Cyclically Adjusted FCF per Share: MXN-237.09 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AGIO Agios Pharmaceuticals Inc MEX:AGIO
47 GF Score
Price MXN1,222.00
GF Value MXN4,349.26
! 3 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Cyclically Adjusted FCF per Share?

Agios Pharmaceuticals MEX:AGIO 47 Cyclically Adjusted FCF per Share is MXN-237.09 as of Jun. 2026. GuruFocus rates MEX:AGIO with a GF Score™ of 47/100 and a GF Value™ of MXN4,349.26. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Agios Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2026 was MXN-24.499. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN-237.09 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Agios Pharmaceuticals was -9.70% per year. The lowest was -11.50% per year. And the median was -10.60% per year.

As of today (2026-08-25), Agios Pharmaceuticals's current stock price is MXN1222.00. Agios Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was MXN-237.09. Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Agios Pharmaceuticals  (MEX:AGIO) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Agios Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Agios Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Agios Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Agios Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -89.12 -98.23 -91.49 -212.34 -277.44

Agios Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -222.28 -187.23 -277.44 -231.90 -237.09

MEX:AGIO vs BHVN, VRDN, ZLAB: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


MEX:AGIO
47GF Score
Agios Pharmaceuticals Inc MEX:AGIO
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agios Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Agios Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-24.499/333.9520*333.9520
=-24.499

Current CPI (Jun. 2026) = 333.9520.

Agios Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -26.312 241.428 -36.396
201612 -25.664 241.432 -35.499
201703 -33.118 243.801 -45.364
201706 -23.210 244.955 -31.643
201709 -29.861 246.819 -40.403
201712 -30.481 246.524 -41.291
201803 -32.761 249.554 -43.841
201806 -23.406 251.989 -31.019
201809 -21.588 252.439 -28.559
201812 -25.385 251.233 -33.743
201903 -34.947 254.202 -45.911
201906 -29.251 256.143 -38.137
201909 -29.419 256.759 -38.264
201912 -29.558 256.974 -38.412
202003 -37.442 258.115 -48.443
202006 -24.081 257.797 -31.195
202009 -23.454 260.280 -30.093
202012 -14.346 260.474 -18.393
202103 -35.789 264.877 -45.122
202106 -38.315 271.696 -47.094
202109 -30.695 274.310 -37.369
202112 -33.483 278.802 -40.106
202203 -36.694 287.504 -42.622
202206 -27.958 296.311 -31.510
202209 -26.183 296.808 -29.460
202212 -23.512 296.797 -26.455
202303 -31.175 301.836 -34.492
202306 -20.579 305.109 -22.524
202309 -24.819 307.789 -26.929
202312 -22.072 306.746 -24.030
202403 -29.437 312.332 -31.475
202406 -23.462 314.175 -24.939
202409 -28.520 315.301 -30.207
202412 -47.565 315.605 -50.330
202503 -39.968 319.799 -41.737
202506 -28.601 322.561 -29.611
202509 -28.304 324.800 -29.102
202512 -30.036 324.054 -30.953
202603 -36.717 330.213 -37.133
202606 -24.499 333.952 -24.499

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN-237.09 mean?
Agios Pharmaceuticals (MEX:AGIO) has a Cyclically Adjusted FCF per Share of MXN-237.09 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Agios Pharmaceuticals and its competitors.
Is Agios Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Agios Pharmaceuticals' current Cyclically Adjusted FCF per Share is MXN-237.09. Overall, Agios Pharmaceuticals has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Cyclically Adjusted FCF per Share compare to BHVN and VRDN?
Agios Pharmaceuticals' Cyclically Adjusted FCF per Share of MXN-237.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Cyclically Adjusted FCF per Share is MXN-237.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Agios Pharmaceuticals (MEX:AGIO) has a current Cyclically Adjusted FCF per Share of MXN-237.09. The stock's GF Value™ is MXN4,349.26, compared to a current price of MXN1,222.00 — trading 71.9% below its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN-237.09. Agios Pharmaceuticals' overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Agios Pharmaceuticals (MEX:AGIO), the current Cyclically Adjusted FCF per Share is MXN-237.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agios Pharmaceuticals (MEX:AGIO) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of MXN1,222.00 is trading 71.9% below its estimated GF Value™ of MXN4,349.26.

Key valuation signals for MEX:AGIO:

  • Cyclically Adjusted FCF per Share: MXN-237.09
  • GF Value™: MXN4,349.26 vs. price of MXN1,222.00 (71.9% below fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the MEX:AGIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
47GF Score

Get the complete analysis for MEX:AGIO

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,222.00
Price
MXN4,349.26
GF Value